Wolff J M, Borchers H, Brehmer B, Brauers A, Jakse G
Department of Urology, RWTH Aachen, Germany.
Urol Int. 1998;60(3):152-5. doi: 10.1159/000030240.
Recently, tissue polypeptide-specific antigen (TPS), a cytokeratin 18 marker, was described to be discriminative between cancer of the prostate (CaP) and benign prostatic hyperplasia (BPH). Cyfra 8/18, a marker which recognizes both cytokeratin 8 and 18 fragments, is discussed to improve sensitivity and specificity of TPS. We investigated whether Cyfra 8/18 serum concentration discriminates between patients with clinically localized CaP and BPH.
Serum Cyfra 8/18 levels were determined in patients with untreated CaP before radical prostatectomy (pT1-3pNoMo; n = 11) and with histologically confirmed BPH (n = 22). Cyfra 8/18 concentration was correlated to the prostate-specific antigen (PSA) concentration.
Median Cyfra 8/18 level was 0.64 ng/ml in CaP patients and 0.57 ng/ml in BPH patients. This difference is statistically not significant (p = 0.91). Furthermore, no correlation to PSA levels could be established (CaP: r = 0.036; BPH: r = 0.09).
In contrast to a recent report we found the Cyfra 8/18 serum concentration to be a nondiscriminative parameter between CaP and BPH.
最近，组织多肽特异性抗原（TPS），一种细胞角蛋白18标志物，被描述为可区分前列腺癌（CaP）和良性前列腺增生（BPH）。细胞角蛋白8/18（Cyfra 8/18），一种可识别细胞角蛋白8和18片段的标志物，被认为可提高TPS的敏感性和特异性。我们研究了Cyfra 8/18血清浓度是否能区分临床局限性CaP患者和BPH患者。
在根治性前列腺切除术前行未治疗的CaP患者（pT1 - 3pNoMo；n = 11）和经组织学证实的BPH患者（n = 22）中测定血清Cyfra 8/18水平。Cyfra 8/18浓度与前列腺特异性抗原（PSA）浓度相关。
CaP患者的Cyfra 8/18水平中位数为0.64 ng/ml，BPH患者为0.57 ng/ml。这种差异在统计学上不显著（p = 0.91）。此外，未发现与PSA水平有相关性（CaP：r = 0.036；BPH：r = 0.09）。
与最近的一份报告相反，我们发现Cyfra 8/18血清浓度在CaP和BPH之间不是一个有鉴别意义的参数。
